Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease
Our experience confirms the efficacy of pasireotide on the UFC, especially in combined regimens, but also the difficulty of restoring circadian rhythm in CD. This is the first study to report metyrapone add-on to pasireotide, but larger studies are needed to further investigate this association. Pasireotide surely worsens glucose homeostasis, but its positive effects, alone or combined, on blood pressure, lipid profile, and body weight justify its use under careful hyperglycemia management.
Authors
- Mattia Barbot (ORCID: https://orcid.org/0000-0002-1081-5727)
- Luca Denaro (ORCID: https://orcid.org/0000-0002-2529-6149)
- Alessandro Mondin (ORCID: https://orcid.org/0000-0002-6046-5198)
- Filippo Ceccato (ORCID: https://orcid.org/0000-0003-1456-8716)
- Renzo Manara (ORCID: https://orcid.org/0000-0002-5130-3971)
- Carla Maria Scaroni (ORCID: https://orcid.org/0000-0001-9396-3815)
- Umberto Maria Robertazzo
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/fendo.2025.1695342
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00